Filter Search for grants
Call Navigation
Deadline expired
The deadline for this call has expired.
Call key data
Call for proposals to support the development of novel antivirals (HERA)
Funding Program
EU4Health programme 2021-2027
Call number
EU4H-2024-PJ-01-4
deadlines
Opening
23.05.2024
Deadline
05.09.2024 17:00
Funding rate
60-80%
Call budget
€ 10,000,000.00
Estimated EU contribution per project
€ 10,000,000.00
Link to the call
Link to the submission
Call content
short description
This action supports the policy priority to be better prepared to respond to serious cross-border health threats. It contributes to the achievement of the EU4Health Programme’s general objective of protecting people in the Union from serious cross-border threats to health and strengthening the responsiveness of health systems and coordination among the Member States to cope with serious cross-border threats to health (Article 3, point (b), of Regulation (EU) 2021/522) through the specific objectives defined in Article 4, points (b) and (c), of Regulation (EU) 2021/522.
Call objectives
This action aims to diversify and advance the pipeline of BSA candidates. More specifically, it will support the development and further characterisation of broad-spectrum antivirals targeting identified HERA priority viral families, which largely can be divided among respiratory RNA viral families, such as Paramyxo-, Orthomyxo and Coronaviridae, as well as those targeting viral families known for causing viral haemorrhagic fever (VHF), such as Arena-, Bunya-, Flavi-, Filoviridae. The action aims to identify a potent BSA candidate, in order to advance its clinical development. A robust pipeline should contain multiple BSA candidates for each viral family that are developed in parallel. When selecting the BSA candidate, attention will be paid to the complementarity with existing Horizon Europe projects.
The proposal would need to cover early safety and efficacy trials for testing new or improved anti-viral therapeutics, with a clear regulatory and clinical pathway, including first in humans.
Innovative delivery systems and suitable safety profiles for broad use should be considered when possible as well as the application of novel approaches and widely applicable workflows (e.g. artificial intelligence) for rapid and reliable identification of broad-spectrum anti-viral therapeutics.
read more
Expected effects and impacts
HERA’s threat assessment of 2022 included a vulnerability analysis with regard to the availability or absence of medical countermeasures, in particular the availability of vaccines and treatment options. Given that the large majority of identified virus families lack effective vaccines and/or effective therapeutics at the EU and global levels, HERA’s long-term aim is to, inter alia, support the creation of a diverse portfolio of BSAs and BCCs that can be further developed in clinical by identifying most promising candidates and supporting their characterisation and assessment, including through clinical trials. Actions funded under this topic are therefore expected to either bring innovative, emerging, and cutting-edge elements with significant economic potential to the internal market or to reduce or prevent strategic dependencies of the Union, including by contributing to the Union's technological leadership in the innovation and development of BSA and enhancing the access to these products in the EU.
read more
Eligibility Criteria
Regions / countries for funding
Moldova (Moldova), Iceland (Ísland), Montenegro (Црна Гора), Norway (Norge), Ukraine (Україна)
eligible entities
Education and training institution, International organization, Non-Profit Organisation (NPO) / Non-Governmental Organisation (NGO), Other, Private institution, incl. private company (private for profit), Public Body (national, regional and local; incl. EGTCs), Research Institution incl. University, Small and medium-sized enterprise (SME)
Mandatory partnership
No
Project Partnership
Applications may be submitted either by a single applicant or a consortium of at least 3 applicants (beneficiaries; not affiliated entities).
In order to be eligible, the applicants (beneficiaries and affiliated entities) must:
- be legal entities (public or private bodies)
- be established in one of the eligible countries, i.e.:
- EU Member States (including overseas countries and territories (OCTs
- eligible non-EU countries: listed EEA countries and countries associated to the EU4Health Programme or countries which are in ongoing negotiations for an association agreement and where the agreement enters into force before grant signature (list of participating countries)
Other entities may participate in other consortium roles, such as associated partners, subcontractors, third parties giving in-kind contributions, etc.
Specific cases:
Natural persons — Natural persons are NOT eligible (with the exception of self-employed persons, i.e. sole traders, where the company does not have legal personality separate from that of the natural person).
International organisations — International organisations are eligible. The rules on eligible countries do not apply to them.
Entities without legal personality — Entities which do not have legal personality under their national law may exceptionally participate, provided that their representatives have the capacity to undertake legal obligations on their behalf, and offer guarantees for the protection of the EU financial interests equivalent to that offered by legal persons.
EU bodies — EU bodies (with the exception of the European Commission Joint Research Centre) can NOT be part of the consortium.
Associations and interest groupings — Entities composed of members may participate as ‘sole beneficiaries’ or ‘beneficiaries without legal personality’. Please note that if the action will be implemented by the members, they should also participate (either as beneficiaries or as affiliated entities, otherwise their costs will NOT be eligible).
European Reference Networks (ERNs) — These cover networks between healthcare providers and centres of expertise in the Member States to reinforce healthcare cooperation, in particular in the area of rare diseases, in line with the objectives set out in Article 12 of Directive 2011/24.
other eligibility criteria
Specific eligibility criteria: Private, academic and public bodies active and in the field of innovation and with proven expertise in development of antivirals.
Financial support to third parties is not allowed.
The costs will be reimbursed at the funding rate fixed in the Grant Agreement (60%).
You can apply for a higher project funding rate (80%) if your project is of ‘exceptional utility’, i.e. concerns:
- actions where at least 30 % of the budget is allocated to Member States whose GNI per inhabitant is less than 90% of the EU average or
- actions with bodies from at least 14 Member States and where at least four are from Member States whose GNI per inhabitant is less than 90% of the EU average.
Additional information
Topics
Relevance for EU Macro-Region
EUSAIR - EU Strategy for the Adriatic and Ionian Region, EUSALP - EU Strategy for the Alpine Space, EUSBSR - EU Strategy for the Baltic Sea Region, EUSDR - EU Strategy for the Danube Region
UN Sustainable Development Goals (UN-SDGs)
project duration
24 months
Additional Information
Proposals must be submitted electronically via the Funding & Tenders Portal Electronic Submission System (accessible via the Topic page in the Search Funding & Tenders section). Paper submissions are NOT possible. Proposals (including annexes and supporting documents) must be submitted using the forms provided inside the Submission System.
Proposals must be complete and contain all the requested information and all required annexes and supporting documents:
-
Application Form Part A — contains administrative information about the participants (future coordinator, beneficiaries and affiliated entities) and the summarised budget for the project (to be filled in directly online)
-
Application Form Part B — contains the technical description of the project (to be downloaded from the Portal Submission System, completed and then assembled and re-uploaded)
-
mandatory annexes and supporting documents (templates available to be downloaded from the Portal Submission System, completed, assembled and re-uploaded):
-
detailed budget table/calculator
-
CVs (standard) of core project team
-
list of previous projects (key projects for the last 4 years) (template available in Part B)
-
Proposals are limited to maximum 70 pages (Part B). Evaluators will not consider any additional pages.
Call documents
Call document EU4H -2024-PJ-01Call document EU4H -2024-PJ-01(1059kB)
Contact
To see more information about this call, you can register for free here
or log in with an existing account.
Log in
Register now